oxelumab (RG4930) / Roche, Genmab - LARVOL DELTA

Long Acting Bispecific Antibody Co-blocking OX40L and TNFα for Hidradenitis Suppurativa (AAAAI 2026) - "In human DC/T cell coculture assay, LQ095 synergistically suppressed GM-CSF production, better than adalimumab, amlitelimab and oxelumab analogue. In cynomolgus monkeys, LQ095 exhibited favorable PK profile with half-life extended to 2-3 times compared to traditional monoclonal antibodies. Conclusions The impressive in vitro and in vivo activity data of LQ095 make it a very promising therapy for HS treatment."

Late-breaking abstract • Dermatology • Graft versus Host Disease • Hidradenitis Suppurativa • Immunology • CSF2 • IL17A • IL2 • TNFA • TNFSF4

Long Acting Bispecific Antibody Co-blocking OX40L and TNFα for Hidradenitis Suppurativa (AAAAI 2026) - "In human DC/T cell coculture assay, LQ095 synergistically suppressed GM-CSF production, better than adalimumab, amlitelimab and oxelumab analogue. The impressive in vitro and in vivo activity data of LQ095 make it a very promising therapy for HS treatment."

Dermatology • Graft versus Host Disease • Hidradenitis Suppurativa • Immunology • CSF2 • IL17A • IL2 • TNFA • TNFSF4

Occurrence of Fasciola (Digenea: Fasciolidae) Species in Livestock, Wildlife and Humans, and the Geographical Distribution of Their Intermediate Hosts in South Africa-A Scoping Review. (PubMed, Front Vet Sci) - "The prevalence of Fasciola spp infection in livestock ranged from 9.1 to 37.67 %, with an estimated annual financial loss ranging from R44930.26-129901 in cattle production in the Eastern Cape province of South Africa. This review reaffirms the scarcity of information on the occurrence and burden of fasciolosis in South Africa, and further highlights the importance of future research covering all provinces of the country and assessing the public health significance of the disease in resource-poor livestock communities in the areas where the parasite is endemic."

Journal • Review • Infectious Disease

Head to head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL-2Rγ mice reconstituted with peripheral blood mononuclear cells. (PubMed, Dis Model Mech) - "These results suggest that oxelumab addresses the pro-inflammatory arm of inflammation while promoting the remodeling arm and that patients exhibiting elevated levels of OX40L may benefit from treatment with oxelumab. Keywords: Ulcerative colitis, NOD/Scid IL2-Rγ, NSG, anti-CD252 antibodies, oxelumab, inflammatory bowel disease."

Head-to-Head • Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD14 • CD52 • IL2 • IL6 • TNFRSF4